15 Apr 2025
16m
Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.